• 한국임상수의학회지
• /
• 제26권4호
• /
• pp.367-370
• /
• 2009

5년령의 암컷 시츄견이 일년 동안의 황달, 복수 등의 증상으로 약물 치료를 받다가 호전을 보이지 않아 내원하였다. 혈액검사 결과 간효소 수치의 상승 및 고글로불린혈증과 저알부민혈증이 확인되었으며, 혈액을 이용한 CAV-1 PCR 검사시 음성임을 확인하였다. 일반 방사선 검사 및 복부 초음파 검사를 통해 간의 크기 감소와 간 실질에서의 저에코성의 다발성 결절 및 복수를 관찰하였고, 복수 검사에서 누출성 복수임을 확인하였다. 복부 CT 검사에서 포도송이 모양으로 조영증강효과를 보이는 다발성 결절이 관찰되었다. 간 생검을 통한 조직병리학적 검사 결과 간 세포의 괴사와 섬유양 세포의 침윤을 확인하였다. 위의 검사 결과를 바탕으로 간경화증으로 진단하였다. 이후 정기적으로 혈액검사, 혈청화학검사, 복부 초음파 검사 및 CT 검사를 실시했다. 내과적 보존적 치료를 실시하였고, 환자는 진단한 지 10개월 후에 사망하였다. 본 증례를 통하여 개에서 간경화증의 CT 영상의 특징을 보고하고자 한다.

• Journal of Yeungnam Medical Science
• /
• 제30권2호
• /
• pp.116-119
• /
• 2013

A burnt-out prostate cancer tumor is a very rare clinical entity. The term 'burnt-out' refers to a primary tumor that has spontaneously and nearly completely regressed without treatment. Since metastasis of prostate cancer is usually encountered in the presence of advanced disease, distant metastasis with an undetectable primary tumor is very rare. We report herein a case of a burnt-out prostate cancer tumor that metastasized to the thoracic (T) spine and caused cord compression. A 66-year-old man visited the Emergency Department due to weakness of both legs for the past two days. His blood and urine tests were normal at the time. His spine magnetic resonance imaging (MRI) scans looked like bone metastasis that involved the T-7 vertebral body and a posterior element, and caused spinal cord compression. Other images, including from the brain MRI, neck/chest/abdomino-pelvic computed tomography (CT) scan and 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) and endoscopy, revealed no lesions that suggested malignancy. After total corpectomy T-7 and screw fixation/fusion at T5 to T10, the pathology report revealed a metastatic carcinoma that was strongly positive for prostate-specific antigen (PSA). The serum PSA value was 1.5 ng/mL. The transrectal 12-core prostate biopsy and ultrasonography showed no definitive hypoechoic lesion, but one specimen had slight (only 1%) adenocarcinoma with a Gleason score of 6 (3+3). The final diagnosis was burned-out prostate cancer with an initial normal PSA value. Although metastatic disease with an unknown primary origin was confirmed, a more aggressive approach in seeking the primary origin could provide a more specific treatment strategy and greater clinical benefit to patients.

• Asian Pacific Journal of Cancer Prevention
• /
• 제14권9호
• /
• pp.5199-5205
• /
• 2013

Background/Aim: The Hippo signaling pathway is a newly discovered and conserved signaling cascade, which regulates organ size control by governing cell proliferation and apoptosis. This study aimed to investigate its effects in human gastric cancer. Methods: Tumor tissues (n=60), adjacent non-tumor tissues (n=60) and normal tissues (n=60) were obtained from the same patients with primary gastric cancer (GC). In addition, 70 samples of chronic atrophic gastritis (CAG) tissues were obtained from patients with intestinal metaplasia (IM) by endoscopic biopsy. Hippo signaling molecules, including Mst1, Lats1, YAP1, TAZ, TEAD1, Oct4 and CDX2, were determined by quantitative polymerase chain reaction (qPCR). Protein expression of Mst1, Lats1, YAP1, TEAD1 and CDX2 was assessed by immunohistochemistry and Western blotting. Results: Mst1, Lats1 and Oct4 mRNA expression showed an increasing tendency from GC tissues to normal gastric tissues, while the mRNA expression of YAP1, TAZ and TEAD1 was up-regulated (all P<0.01). Mst1 and Lats1 protein expression presented a similar trend with their mRNA expression. In addition, YAP1 and TEAD1 protein expression in GC was significantly higher than in the other groups (all P<0.01). CDX2 mRNA and protein expression in the CAG group were higher than in the other groups (all P<0.01). In GC, mRNA expression of Mst1, Lats1, Oct4, YAP1, TAZ, TEAD1 and CDX2 had a close correlation with lymphatic metastasis and tumor TNM stage (all P<0.01). Furthermore, protein expression of Mst1, Lats1, YAP1, TAZ, TEAD1 and CDX2 had a close correlation between each other (P<0.05). Conclusion: The Hippo signaling pathway is involved in the development, progression and metastasis of human gastric cancer. Therefore, manipulation of Hippo signaling molecules may be a potential therapeutic strategy for gastric cancer.

• 대한영상의학회지
• /
• 제79권5호
• /
• pp.259-263
• /
• 2018

52세 남자 환자가 우측 유방의 바깥부위에서 무통의 단단한 종괴를 호소하였다. 흉부 CT에서 3.3 cm 크기의 원형의 미세소엽상 경계의 조영증강되는 종괴가 확인되었고, 초음파에서는 미세소엽상 경계를 보이는 저에코성 종괴로, 종괴의 내부에는 석회화와 혈류가 보였다. 중심부바늘생검에서 종괴는 양성 과립세포종양(granular cell tumor; 이하 GCT)으로 확진되었다. 환자는 타병원으로 전원되어 병변의 수술적 제거를 시행하였다. 과립세포종양은 슈반세포(schwann cell)에 유래하는 종양으로, 유방에서는 드물고 대부분은 양성이다. 과립세포종양의 임상적 및 방사선학적 특징은 악성 종양과 유사한 소견을 보여 감별이 어려운 경우가 있으며, CT 영상은 거의 보고된 바가 없다. 본 증례를 통해 임상의와 방사선 전문의가 드물지만 양성종양인 GCT의 영상의학적 특징을 알고, 이를 악성종양과 감별하여 과도한 치료를 피해야 할것이다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권11호
• /
• pp.4603-4608
• /
• 2015

Background: To determine the potential value of serum tumor markers in predicting pCR (pathological complete response) during neoadjuvant chemotherapy. Materials and Methods: We retrospectively monitored the pro-, mid-, and post-neoadjuvant treatment serum tumor marker concentrations in patients with locally advanced breast cancer (stage II-III) who accepted pre-surgical chemotherapy or chemotherapy in combination with targeted therapy at Fudan University Shanghai Cancer Center between September 2011 and January 2014 and investigated the association of serum tumor marker levels with therapeutic effect. Core needle biopsy samples were assessed using immunohistochemistry (IHC) prior to neoadjuvant treatment to determine hormone receptor, human epidermal growth factor receptor 2(HER2), and proliferation index Ki67 values. In our study, therapeutic response was evaluated by pCR, defined as the disappearance of all invasive cancer cells from excised tissue (including primary lesion and axillary lymph nodes) after completion of chemotherapy. Analysis of variance of repeated measures and receiver operating characteristic (ROC) curves were employed for statistical analysis of the data. Results: A total of 348 patients were recruited in our study after excluding patients with incomplete clinical information. Of these, 106 patients were observed to have acquired pCR status after treatment completion, accounting for approximately 30.5% of study individuals. In addition, 147patients were determined to be Her-2 positive, among whom the pCR rate was 45.6% (69 patients). General linear model analysis (repeated measures analysis of variance) showed that the concentration of cancer antigen (CA) 15-3 increased after neoadjuvant chemotherapy in both pCR and non-pCR groups, and that there were significant differences between the two groups (P=0.008). The areas under the ROC curves (AUCs) of pre-, mid-, and post-treatment CA15-3 concentrations demonstrated low-level predictive value (AUC=0.594, 0.644, 0.621, respectively). No significant differences in carcinoembryonic antigen (CEA) or CA12-5 serum levels were observed between the pCR and non-pCR groups (P=0.196 and 0.693, respectively). No efficient AUC of CEA or CA12-5 concentrations were observed to predict patient response toward neoadjuvant treatment (both less than 0.7), nor were differences between the two groups observed at different time points. We then analyzed the Her-2 positive subset of our cohort. Significant differences in CEA concentrations were identified between the pCR and non-pCR groups (P=0.039), but not in CA15-3 or CA12-5 levels (p=0.092 and 0.89, respectively). None of the ROC curves showed underlying prognostic value, as the AUCs of these three markers were less than 0.7. The ROC-AUCs for the CA12-5 concentrations of inter-and post-neoadjuvant chemotherapy in the estrogen receptor negative HER2 positive subgroup were 0.735 and 0.767, respectively. However, the specificity and sensitivity values were at odds with each other which meant that improving either the sensitivity or specificity would impair the efficiency of the other. Conclusions: Serum tumor markers CA15-3, CA12-5, and CEA might have little clinical significance in predicting neoadjuvant treatment response in locally advanced breast cancer.